Office of the Press Secretary

President Clinton Announces Major New Investment in Diabetes Research, Treatment, and Prevention (7/13/00)

Urges Congress to Fully Fund Racial Disparities Health Initiative

Today, at the national conference of the NAACP, the President will announce that the National Institutes of Health and the Juvenile Diabetes Foundation will immediately release $5 million to 10 research sites worldwide to fund new clinical trials attempting to replicate the breakthrough "islet transplantation" protocol that has apparently cured a small number of individuals with Type 1 diabetes.

He will also highlight that the Administration’s Mid-Session review budget commits another $300 million over five years for research on and prevention of all types of diabetes. As he outlines this major new financing commitment, the President will unveil findings from a new report documenting that adolescent birth rates, infant mortality, and childhood immunization rates are improving across all segments of the youth populations, including minorities. However, the President will also note that racial disparities in health status persist, and call on the Congress to fully fund the Administration’s initiative to improve health outcomes and eliminate health disparities amongst American minority populations. Today, the President will:

ANNOUNCE SIGNIFICANT NEW FUNDING INVESTMENT IN DIABETES RESEARCH AND PREVENTION. Approximately 16 million people nationwide have diabetes, a chronic disease with no cure that costs the health care system approximately $98 billion annually. Diabetes is the leading cause of new cases of blindness in people aged 20 to 74, affecting up to 24,000 people each year. It is also the leading cause of non-traumatic lower-limb amputations - more than 56,000 a year. In addition, people with diabetes are more than twice as likely to have heart disease or a stroke than people without the disease. One in four African American women over the age of 55 has diabetes, and African Americans are more likely to have diabetes than whites.

• New investment in breakthrough clinical trials treating Type 1 Diabetes. Today, President Clinton will announce that the National Institutes of Health will invest $5 million, as part of a larger public private partnership between NIH and the Juvenile Diabetes Foundation, in 10 sites worldwide in an attempt to replicate the breakthrough islet transplantation technique demonstrated to have effectively cured Type 1 diabetes in a small number of patients. There are approximately one million individuals with Type 1 diabetes nationwide, approximately 25 percent of which are minorities, and 30,000 new cases are diagnosed every year - 13,000 in children.
• Highlighted new investment of $150 million over 5 years in research on diabetes proposed in mid-session review. The President’s Mid-Session review budget includes $150 million over five additional years at the National Institutes of Health and the Centers for Disease Control and Prevention for new research on treatment and prevention of Type 1 diabetes, including ways to understand and address the immune system abnormalities that cause the disease and combat complications of the disease.
• Highlighted new investment of $150 million over five additional years to prevent and treat diabetes in Native American populations. The President’s Mid-Session review budget includes approximately $ 150 million for over 300 tribal grant programs to prevent the development of Type 2 diabetes in individuals at risk and enhance the diabetes care and education provided at Indian Health Service clinics through the creation of new diabetes clinics and teams of health care professionals dedicated to diabetes care.
• Highlighted investment of at least $65 million in new or expanded initiatives dedicated to research on and prevention of Type 2 diabetes in his FY 2001 budget. President Clinton announced that his FY 2001 budget proposes to dedicate at least $65 million to research on Type 2 diabetes, as part of an overall investment at NIH of $561 million in diabetes research. This new funding will be used to fund clinical trials aimed at developing more effective treatment; prevention strategies and national education efforts for Type 2 diabetes; research on risk factors for development and progression of complications for diabetes; and the reasons for racial disparities in the incidence of diabetes. This funding will also be used to expand and speed the search for genes indicating a predisposition to Type 2 diabetes and basic scientific research on the molecular basis for the disease.

The Centers selected for the ITN Clinical Trials are:

• University of Alberta Clinical Islet Transplantation Program, Edmonton, Canada
• Diabetes Research Institute, University of Miami, Miami, Florida
• Diabetes Institute for Immunology and Transplantation, University of Minnesota, Minneapolis, Minnesota
• Juvenile Diabetes Foundation Center for Islet Transplantation, Harvard Medical School, Boston, Massachusetts
• Diabetes Research Training Center, Washington University, St. Louis, Missouri
• Pacific Northwest Research Institute, Seattle, Washington
• Organ/Tissue Transplant Research Center, National Institutes of Health, Bethesda, Maryland
• Islet Transplant Centre, Justis-Liebig University, Giessen, Germany
• San Raffaele Scientific Institute, University of Milan, Milan, Italy
• University Hospital, Geneva, Switzerland